593 reports of this reaction
2.3% of all ALISKIREN HEMIFUMARATE reports
#2 most reported adverse reaction
BLOOD PRESSURE INCREASED is the #2 most commonly reported adverse reaction for ALISKIREN HEMIFUMARATE, manufactured by LXO US Inc.. There are 593 FDA adverse event reports linking ALISKIREN HEMIFUMARATE to BLOOD PRESSURE INCREASED. This represents approximately 2.3% of all 26,137 adverse event reports for this drug.
Patients taking ALISKIREN HEMIFUMARATE who experience blood pressure increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD PRESSURE INCREASED is a less commonly reported adverse event for ALISKIREN HEMIFUMARATE, but still significant enough to appear in the safety profile.
In addition to blood pressure increased, the following adverse reactions have been reported for ALISKIREN HEMIFUMARATE:
The following drugs have also been linked to blood pressure increased in FDA adverse event reports:
BLOOD PRESSURE INCREASED has been reported as an adverse event in 593 FDA reports for ALISKIREN HEMIFUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD PRESSURE INCREASED accounts for approximately 2.3% of all adverse event reports for ALISKIREN HEMIFUMARATE, making it one of the most commonly reported side effect.
If you experience blood pressure increased while taking ALISKIREN HEMIFUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.